Transmembrane helices are an over-presented and evolutionarily conserved source of major histocompatibility complex class I and II epitopes

Richèl J.C. Bilderbeek [1], **Maksim V. Baranov** [1], **Geert van den Bogaart** [1] **and Frans Bianchi** [1,*]

[1] *Molecular Immunology, GBB, University of Groningen, Groningen, The Netherlands*

Correspondence*:
Frans Bianchi, Nijenborgh 7, 9747 AG Groningen
f.bianchi@rug.nl

2 ABSTRACT

3 Cytolytic T cell responses are predicted to be biased towards membrane proteins. The peptide-
4 binding grooves of most alleles of histocompatibility complex class I (MHC-I) are relatively
5 hydrophobic, therefore peptide fragments derived from human transmembrane helices (TMHs)
6 are predicted to be presented more often as would be expected based on their abundance in the
7 proteome. However, the physiological reason of why membrane proteins might be over-presented
8 is unclear. In this study, we show that the predicted over-presentation of TMH-derived peptides
9 is general, as it is predicted for bacteria and viruses and for both MHC-I and MHC-II, and
10 confirmed by re-analysis of epitope databases. Moreover, we show that TMHs are evolutionarily
11 more conserved, because single nucleotide polymorphisms (SNPs) are present relatively less
12 frequently in TMH-coding chromosomal regions compared to regions coding for extracellular and
13 cytoplasmic protein regions. Thus, our findings suggest that both cytolytic and helper T cells are
14 more tuned to respond to membrane proteins, because these are evolutionary more conserved.
15 We speculate that TMHs are less prone to mutations that enable pathogens to evade T cell
16 responses.

17 **Keywords: antigen presentation, membrane proteins, adaptive immunity, transmembrane domain, epitopes, MHC-I, MHC-II,**
18 **evolutionary conservation**

1 INTRODUCTION

19 Our immune system fights diseases and infections from pathogens, such as fungi, bacteria or viruses. An
20 important part of the acquired immune response, that develops specialized and more specific recognition of
21 pathogens than the innate immune response, are T cells which recognize peptides, called epitopes, derived
22 from antigenic proteins presented on Major Histocompatibility Complexes (MHC) class I and II on the cell
23 surface.

24 The MHC proteins are heterodimeric complexes encoded by the HLA (Human Leukocyte Antigens)
25 genes. In humans, the peptide binding groove of MHC-I is made by only the alpha subunit. There are
26 three classical alleles of MHC-I, hallmarked by a highly polymorphic alpha chain called HLA-A, HLA-B

and HLA-C, that all present epitopes to cytolytic T cells. For MHC-II, both the alpha and the beta chains contribute to the peptide binding groove. There are three classical alleles of MHC-II as well, called HLA-DR, HLA-DQ and HLA-DP, that all present epitopes to helper T cells. Each MHC complex can present a subset of all possible peptides. For example, HLA-A and HLA-B have no overlap in which epitopes they bind (Lund et al., 2004). Moreover, the HLA genes of humans are highly polymorphic, with hundreds to thousands of different alleles, and each different allele presents a different subset of peptides (Marsh et al., 2010).

Humans express a limited set of MHC alleles and therefore an individual's immune system detects only a fraction of all possible peptide fragments. However, at the population level, the coverage of pathogenic peptides that are detected is very high, because of the highly polymorphic MHC genes. It is therefore believed that MHC polymorphism improves immunity at the population level, as mutations in a protein that disrupt a particular MHC presentation at the individual level, so-called escape mutations, will not affect MHC presentation for all alleles present in the population (Sommer, 2005).

Many studies are aimed at identifying the repertoire of epitopes that are presented in any of the different alleles to determine which epitopes will result in an immune response, as this will for instance aid the design of vaccines. These studies have led to the development of prediction algorithms that allow for very reliable *in silico* predictions of the peptide binding affinities (Larsen et al., 2010; Schellens et al., 2008; Tang et al., 2011). For example, S. Tang et al. (Tang et al., 2011) found that, of the 432 peptides that were predicted to bind to an MHC allele, 86% were experimentally confirmed to do so.

Using these prediction algorithms, we recently showed that peptides derived from transmembrane helices (TMHs) are likely to be more frequently presented by MHC-I than expected based on their abundance (Bianchi et al., 2017), which is in line with a previous study by Istrail et al (Istrail et al., 2004), demonstrating that N-terminal signal sequences are likely to be presented within major histocompatibility complexes, due their hydrophobic nature. Moreover, we showed that some well-known immunodominant peptides stem from TMHs. This over-presentation is attributed to the fact that the peptide-binding groove of most MHC-I alleles is relatively hydrophobic, and therefore hydrophobic TMH-derived peptides have a higher affinity to bind than their soluble hydrophilic counterparts.

TMHs are hydrophobic as they need to span the hydrophobic lipid bilayer of cellular membranes. They consist of an alpha helix of, on average, 23 amino acids in length. TMHs can also be predicted with high accuracy from a protein sequence by bioinformatics approaches (Krogh et al., 2001; Käll et al., 2004; Arai et al., 2004; Jones, 2007; Klammer et al., 2009; Wang et al., 2019). For example, a study by Jones (Jones, 2007) found that, from 184 transmembrane proteins (TMPs) with known topology, 80% of the TMH predictions of these proteins matched the experimental findings. TMHs are common structures in the proteins of humans and microbes. Different TMH prediction tools estimate that 15-39% of all proteins in the human proteome contain at least one TMH (Ahram et al., 2006). However, the physiological reason why peptides derived from TMHs would be presented more often than peptides stemming from soluble (i.e., extracellular or cytoplasmic) protein regions is unknown. In this study, we hypothesized that the presentation of TMH residues is evolutionarily preferred, since TMHs are less prone to undergo escape mutations. One reason to expect such a reduced variability (and hence evolutionary conservation) in TMHs, is that these are restricted in their variability by the functional requirement to span a lipid bilayer. This limits many of the amino acids present in TMHs to have hydrophobic side chains (Hessa et al., 2007; Jones et al., 1994). Therefore, we speculated that the TMHs of pathogens might have a lower chance to develop escape mutations, as that will result in a dysfunctional TMH and render the protein inactive.

2

This study had two objectives. First, we aimed to generalize our findings by predicting the antigenic presentation from different kingdoms of life in both MHC-I and -II. From these *in silico* predictions, we conclude that TMH-derived epitopes from a human, viral and bacterial proteome are likely to be presented more often than expected by chance for most alleles of MHC-I and II. We confirmed the presentation of TMH-derived peptides by re-analysis of peptides from The Immune Epitope Database (IEDB) (Vita et al., 2019). Second, we tested our hypothesis that TMHs are more evolutionary conserved than soluble protein regions. Our analysis of human single nucleotide polymorphisms (SNPs) showed that random point mutations are indeed less likely to occur within TMHs. These findings strengthen the emerging notion that TMHs are important for the T cell-mediated adaptive immune system, and hence are of importance in vaccine development.

2 METHODS

2.1 Predicting TMH epitopes

To predict how frequently epitopes overlapping with TMHs are presented, a similar analysis strategy was applied as described in (Bianchi et al., 2017) for several alleles of both MHC-I and MHC-II, and for a human, viral and bacterial proteome. To summarize, for each proteome, all possible 9-mers (for MHC-I) or 14-mers (MHC-II) were derived. For each of these peptides, we determined if it overlapped with a predicted TMH and if it was predicted to bind to the most frequent alleles of each MHC allele.

For MHC-I, 9-mers were used, as this is the length most frequently presented in MHC-I and was used in our earlier study (Bianchi et al., 2017). For MHC-II, 14-mers were used, as this is the most frequently occurring epitope length (Bergseng et al., 2015). A human (UniProt ID UP000005640_9606), viral (SARS-CoV-2, UniProt ID UP000464024) and bacterial (*Mycobacterium tuberculosis*, UniProt ID UP000001584) reference proteome was used. TMHMM (Krogh et al., 2001) was used to predict the topology of the proteins within these proteomes. To predict the affinity of an epitope to a certain HLA allele, EpitopePrediction (Bianchi et al., 2017) for MHC-I and MHCnuggets (Shao et al., 2020) for MHC-II was used. Both MCH-I and MHC-II alleles were selected to have a high prevalence in the population, where the alleles of MHC-I are the alleles representing the 13 supertypes with over 99.6% coverage of the population's MHC-I repertoire as defined by (Lund et al., 2004) (Sette and Sidney, 1999), and the 21 MHC-II alleles, have a phenotypic frequency of 14% or more in the human population (Greenbaum et al., 2011).

We define a protein to be a binder if, for a certain MHC allele, any of its 9-mer or 14-mer peptides have an IC50 value in the lowest 2% of all peptides within a *proteome* (see supplementary Tables ST1 and ST2 for values), this differs from our previous study where we defined a binder as having an IC50 in the lowest 2% of the peptides within a *protein*. This revised definition precludes bias of proteins that give rise to no or only very few MHC epitopes. To verify that the slight change in method yields similar results, a side by side comparison is shown in the supplementary materials, Figures S1 and S2.

2.2 TMH epitopes obtained from experimental data

To obtain experimental confirmation that peptides stemming from TMHs are presented by MHC-I and MHC-II, we mined the IEDB (Vita et al., 2019) for confirmed human MHC-ligands. We queried the IEDB for all linear epitopes obtained from MHC ligand assays in healthy humans, carrying the MHC alleles as used in this study. From these epitopes, we kept those that were present exactly once in the human reference proteome with UniProt ID UP000005640_9606. We concluded that the epitope overlapped with

110 a TMH if at least 1 amino acid was overlapping with a TMH, as predicted with `TMHMM` Krogh et al.
111 (2001). The full analysis can be found at `https://github.com/richelbilderbeek/bbbq_`
112 `article_issue_157`.

2.2.1 Evolutionary conservation of TMHs

114 To determine the evolutionary conservation of TMHs, we first collected human single nucleotide
115 polymorphisms (SNPs) resulting in a single amino acid substitution and determined if this occurred
116 within a predicted TMH or not.

117 As a data source, multiple NCBI (`https://www.ncbi.nlm.nih.gov/`) databases were used:
118 the *dbSNP* (Sherry et al., 2001) database, which contains 650 million cataloged non-redundant human
119 variations (called *RefSNPs*, `https://www.ncbi.nlm.nih.gov/snp/docs/RefSNP_about/`),
120 and the databases *gene* (for gene names (Brown et al., 2015)) and *protein* (for proteins sequences (Sayers
121 et al., 2010)).

122 The first query was a call to the *gene* database for the term 'membrane protein' (in all fields) for the
123 organism *Homo sapiens*. This resulted in 1,077 gene IDs (on December 2020). The next query was a call to
124 the *gene* database to obtain the gene names from the gene IDs. Per gene name, the *dbSNP* NCBI database
125 was queried for variations associated with the gene name. As the NCBI API constrains its users to three
126 calls per second (to assure fair use), we had to limit the extent of our analysis.

127 The number of SNPs was limited to the first 250 variations per gene, resulting in ≈61k variations. Only
128 variations that result in a SNP for a single amino acid substitution were analyzed, resulting in ≈38k SNPs.
129 The exact amounts can be found in the supplementary materials, Tables ST3 and ST4.

130 SNPs were picked based on ID number, which is linked to their discovery date. To verify that these
131 ID numbers are unrelated to SNP positions, the relative positions of all analyzed SNPs in a protein were
132 determined. This analysis showed no positional bias of the SNPs, as shown in supplementary figure S3.

133 Per SNP, the *protein* NCBI database was queried for the protein sequence. For each protein sequence, the
134 protein topology was determined using `PureseqTM`. Using these predicted protein topologies, the SNPs
135 were scored to be located within or outside TMHs.

3 RESULTS

3.1 TMH-derived peptides are predicted to be over-presented in MHC-I

137 Figure 1A shows the predicted presentation of TMH-derived peptides in MHC-I, for a human, viral
138 and bacterial proteome. Per MHC-I allele, it shows the percentage of binders that overlap with a TMH
139 with at least one residue. The horizontal line shows the expected percentage of TMH-derived epitopes
140 that would be presented, if TMH-derived epitopes would be presented just as likely as epitopes derived
141 from soluble regions, when assuming equal incidence of soluble and TMH-derived epitope presentation.
142 For 11 out of 13 MHC-I alleles, TMH-derived epitopes are predicted to be presented more often than the
143 null expectation, for a human and bacterial proteome. For the viral proteome, 12 out of 13 MHC-I alleles
144 present TMH-derived epitopes more often than expected by chance. The extent of the over-presentation
145 between the different alleles is similar for the probed proteomes, which strengthens our previous conclusion
146 (Bianchi et al., 2017) that the hydrophobicity of the MHC-binding groove is the main factor responsible for
147 the predicted over-presentation of TMH-derived peptides.

3.2 TMH-derived peptides are predicted to be over-presented in MHC-II

We next wondered if the over-representation of TMH-derived peptides would also be present for MHC-II. Figure 1A shows the percentages of MHC-II epitopes predicted to be overlapping with TMHs for our human, viral and bacterial proteomes. We found that TMH-derived peptides are over-presented in all of the 21 MHC-II alleles, for a human, bacterial and viral proteome, except for `HLA-DRB3*0101` in *M. tuberculosis*. See supplementary Table ST5 for the exact TMH and epitope counts.

3.3 The over-presentation of TMH-derived peptides is caused by the hydrophobicity of the MHC peptide binding groove

For MHC-I, we previously showed that the over-presentation of TMH-derived peptides is caused by the hydrophobicity of the peptide binding grooves (Bianchi et al., 2017). Figures 1B and 1C show the extent of over-presentation of TMH-derived epitopes as a function of the hydrophobicity preference score for the different human MHC alleles. An assumed linear correlation explains 88% of the variability in MHC-I. For MHC-II, 62% of the variability is explained by hydrophobicity. This indicates that TMH-derived peptides are over-presented, because the peptide binding grooves of most MHC-I and -II alleles are relatively hydrophobic.

3.4 Experimental validation of presentation of TMH-derived peptides

The Immune Epitope Database (IEDB) from the National Institutes of Health contains millions of linear epitope sequences obtained by MHC ligand assays. For the MHC alleles used in this study, we obtained 54,303 and 2,484 linear epitope sequences for the MHC-I and MHC-II alleles from human origin respectively. There are relatively few epitopes for MHC-II, as MHC-II has many more different alleles than MHC-I, whereas we selected only the human epitopes found for the 21 MHC-II alleles used in this study.

Figure 2A and S4 show there are similar levels of over-presentation of TMH-derived epitopes between (1) the percentage of TMH-derived epitopes that is reported in the IEDB database versus (2) the percentage of TMH-derived epitopes that is predicted to be presented in MHC-I alleles. For MHC-II alleles, there were too few epitopes per MHC allele to result in an informative figure.

In figure 2B we grouped all the epitopes presented by MHC-I and MHC-II alleles by the percentage of TMH-derived epitopes, which are 22% and 10%, respectively.

These findings robustly confirm that epitopes derived from human TMHs are presented in both MHC-I and MHC-II, and support that they are over-presented. See the supplementary Table ST6 for the exact values.

We also mined the IEDB database for epitopes for any type of T cell response from the specified alleles. From the total reports, 36% and 7% concerned TMH-derived epitopes in MHC class I and II, respectively (see Figure S5).

This data confirms that not only TMH derived epitopes are presented on MHC, but this also elicits T-cell mediated immune responses.

3.5 Human TMHs are evolutionarily conserved

We addressed the question whether there is an evolutionary advantage in presenting TMHs. We determined the conservation of TMHs by comparing the occurrences of SNPs located in TMHs or soluble protein regions for the genes coding for membrane proteins. We obtained 911 unique gene names associated with

the phrase 'membrane protein', which are genes coding for both membrane-associated proteins (MAPs, which have no TMH) and transmembrane proteins (TMPs, which have at least one TMH). These genes are linked to 4,780 protein isoforms, of which 2,553 are predicted to be TMPs and 2,237 proteins are predicted to be MAPs. We obtained 37,630 unique variations, of which 9,621 are SNPs that resulted in a straightforward amino acids substitution, of which 6,062 were located in predicted TMPs. See supplementary Tables ST3 and ST4 for the detailed numbers and distributions of SNPs.

Per protein, we calculated two percentages: (1) the percentage of a protein sequence length bearing TMHs, and (2) the percentage of SNPs located within these predicted TMHs. Each percentage pair was plotted in figure 3A. The proportion of SNPs found in TMHs varied from none (i.e., all SNPs were in soluble regions) to all (i.e., all SNPs were in TMHs). To determine if SNPs were randomly distributed over the protein, we performed a linear regression analysis, and added a 95% confidence interval on this regression. This linear fit nearly goes through the origin and has a slope below the line of equality, which shows that less SNPs are found in TMHs than expected by chance.

We determined the probability to find the observed amount of SNPs in TMHs by chance, i.e., when assuming SNPs occur just as likely in soluble domains as in TMHs. We used a binomial Poisson distribution, where the number of trails (n) equals the number of SNPs, which is 21,208. The probability of success for the ith TMP (p_i), is the percentage of residues within a TMH per TMP. These percentages are shown as a histogram in figure 3B. The expected number of SNPs expected to be found in TMHs by chance equals $\sum p \approx 4,141$. As we observed 3,803 SNPs in TMHs, we calculated the probability of having that amount or less successes. We used the type I error cut-off value of $\alpha = 2.5\%$. The chance to find, within TMHs, this amount or less SNPs equals $6.8208 \cdot 10^{-11}$. We determined the relevance of this finding, by calculating how much less SNPs are found in TMHs, when compared to soluble regions, which is the ratio between the number of SNPs found in TMHs versus the number of SNPs as expected by chance. In effect, per 1000 SNPs found in soluble protein domains, one finds 918 SNPs in TMHs, as depicted (as percentages) in figure 3C.

We split this analysis for TMPs containing only a single TMH (so-called single-membrane spanners) and TMPs containing multiple TMHs (multi-membrane spanners). We hypothesized that single-membrane spanners are less conserved than multi-membrane spanners, because multi-membrane spanners might have protein-protein interactions between their TMHs, for example to accommodate active sites, and thus might have additional structural constraints. From the split data, we did the same analysis as for the total TMPs. Figure 4A shows the percentages of TMHs for individual proteins as a function of the percentage of SNPs located in TMHs. For both single- and multi-spanners, a linear regression shows that less SNPs are found in TMHs, than expected by chance.

We also determined the probability to find the observed amount of SNPs by chance in single- and multi-spanners. For single-spanners, we found 452 SNPs in TMH, where ≈ 462 were expected by chance. The chance to observe this or a lower number by chance is 0.319. As this chance was higher than our $\alpha = 0.025$, we consider this no significant effect. For the multi-spanners, we found 3,351 SNPs in TMH, where $\approx 3,678$ were expected by chance. The chance to observe this or a lower number by chance is $8.315841 \cdot 10^{-12}$, which means this number is significantly less as explained by variation. The TMHs of multi-spanners are thus significantly more conserved than soluble protein regions, whereas this is not the case for single-spanners.

Also, for single- and multi-spanners, we determined the relevance of this finding by calculating where and how much less SNPs are found in TMHs when compared to soluble regions, as depicted in Figure

230 4B and 4C. In effect, per 1,000 SNPs found in soluble protein domains, one finds 978 SNPs in TMHs of
231 single-spanners and 911 SNPs in TMHs of multi-spanners.

4 DISCUSSION

232 Epitope prediction is important to understand the immune system function and for the design of vaccines.
233 In this study, we provide evidence that epitopes derived from TMHs are a major source of MHC epitopes.
234 Our bioinformatics predictions indicate that the TMH-derived epitope repertoire is larger than expected by
235 chance for both MHC-I and MHC-II, regardless of the organism. Moreover, reanalysis of MHC-ligands
236 from the IEDB database confirmed the presentation of TMH-derived epitopes. Therefore, it seems likely that
237 TMH-derived epitopes would also result in enhanced T cell responses, although the conservation of TMHs
238 might promote the deletion of T cells responsive to TMH-derived epitopes by central tolerance mechanisms.
239 Finally, our SNP analysis shows that TMHs are evolutionary more conserved than solvent-exposed protein
240 regions.

4.1 Mechanism of MHC presentation of TMH-derived epitopes

242 Although our data show that TMH-derived epitopes are presented in all classical MHC-I and MHC-II
243 alleles, the molecular mechanisms of how integral membrane proteins are processed for MHC presentation
244 are largely unknown (Bianchi et al., 2017). Most prominently, the fundamental principles of how TMHs
245 are extracted from their hydrophobic lipid environments into the aqueous vacuolar lumen, leading to
246 subsequent proteolytic processing are unresolved.

247 A first possibility is that the extraction of TMPs from the membrane is mediated by the ER-associated
248 degradation (ERAD) machinery. For MHC class I (MHC-I) antigen presentation of soluble proteins, the
249 loading of the epitope primarily occurs at the endoplasmatic reticulum (ER). The chaperones tapasin
250 (TAPBP), ERp57 (PDIA3), and calreticulin (CALR) (Rock et al., 2016) first assemble and stabilize the
251 heavy and light chains of MHC-I. Later, this complex binds to the transporter associated with antigen
252 processing (TAP) leading to the formation of the so-called peptide-loading complex (PLC). The PLC drives
253 import of peptides into the ER and mediates their subsequent loading into the peptide-binding groove of
254 MHC-I (Blees et al., 2017). Membrane proteins first will have to be extracted from the membrane before
255 they become amenable to this MHC-I loading by the PLC. In the ER, this process can be orchestrated by
256 the ERAD machinery, consisting of several chaperones that recognize TMPs, ubiquitinate them, and extract
257 them from the ER membrane into the cytosol (retrotranslocation) for proteasomal degradation (Preston and
258 Brodsky, 2017; Meusser et al., 2005). Similar to the peptides generated from soluble proteins, the TMP-
259 derived peptides might then be re-imported by TAP into the ER for MHC-I loading. This ERAD-driven
260 antigen retrotranslocation might be facilitated by lipid bodies (LBs) (Bougnères et al., 2009), since LBs
261 can serve as cytosolic sites for ubiquitination of ER-derived cargo (Fujimoto and Ohsaki, 2006).

262 A second possibility is that TMPs are proteolytically processed by intramembrane proteases that cleave
263 TMHs while they are still membrane embedded. Supporting this hypothesis is the well-established notion
264 that peptides generated by signal peptide peptidases (SPPs), an important class of intramembrane proteases
265 that cleave TMH-like signal sequences, are presented on a specialized class of MHC-I called HLA-E
266 (Oliveira and van Hall, 2015). The loading of peptides generated by SPP onto MHC-I does not depend
267 on the proteosome and TAP, possibly because the peptides are directly released into the lumen of the ER
268 (Oliveira and van Hall, 2015). However, this mechanism cannot explain how most membrane proteins can be
269 processed for antigen presentation, because SPPs only cleave TMH-like signal sequences at their C-termini,
270 and N-terminal domains will hence not be removed. Nevertheless, the presentation of peptides with a high

hydrophobicity index was shown to be independent of TAP as well (Lautscham et al., 2001), suggesting that the TMH peptides might perhaps be released directly in the ER lumen by other intramembrane proteases.

A third possibility is that peptide processing and MHC-loading occur in multivesicular bodies (MVBs) (Oliveira and van Hall, 2015). TMPs can be routed from the plasma membrane and other organelles by vesicular trafficking to endosomes. Eventually, these TMPs can be sorted by the endosomal sorting complexes required for transport (ESCRT) pathway into luminal invaginations that pinch off from the limiting membrane and form intraluminal vesicles. This thus results in MVBs where the membrane proteins destined for degradation are located in intraluminal vesicles. Upon the fusion of MVBs with lysosomes, the entire intraluminal vesicles including the TMPs are degraded (Gruenberg, 2020). Via this mechanism, TMPs might well be processed for antigen presentation, particularly since the loading of MHC-II molecules is well understood to occur in MVBs (Kleijmeer et al., 2001; Peters et al., 1991; Zwart et al., 2005). However, such processing of membrane proteins in MVBs for antigen presentation poses a problem, because complexes of HLA-DR with its antigen-loading chaperon HLA-DM were only observed on intraluminal vesicles, but not on the limiting membranes of MVBs (Zwart et al., 2005), indicating that epitope loading of MHC-II also occurs at intraluminal vesicles. This observation hence raises the question how the intraluminal vesicles carrying the TMPs destined for antigen presentation can be selectively degraded, while the intraluminal vesicles carrying the MHC-II remain intact. A second problem is that phagosomes carrying internalized microbes lack intraluminal vesicles, and it is hence unclear how TMPs from these microbes would be routed to MVBs for MHC-II loading (Zwart et al., 2005).

Alternatively to the enzymatic degradation of lipids in MVBs by lipases (Sander et al., 2016; Gilleron et al., 2016), they might be oxidatively degraded by reactions with radical oxygen species produced by the NADPH oxidase NOX2 (Dingjan et al., 2016). This oxidation can result in a destabilization and disruption of membranes (Dingjan et al., 2016) and might thereby lead to the extraction of TMPs. Due to the hydrophobic nature of TMHs, however, the extracted proteins will likely aggregate and it is unclear how these aggregates would be processed further for MHC loading.

4.2 Evolutionary conservation of TMHs

In general, one might expect that evolutionary selection shapes an immune system where surveillance is directed towards protein regions essential for the survival, proliferation and/or virulence or pathogenic microbes, as these will be most conserved. In SARS-CoV-2, for example, there is preliminary evidence that the strongest selection pressure is directed upon residues that change its virulence (Velazquez-Salinas et al., 2020). These regions, however, may only account for a small part of a pathogen's proteome. Additionally, the structure and function of these essential regions might differ widely between different pathogenic proteins. Because of this scarcity and variance in targets, one can imagine that it will be mostly unfeasible to provide innate immune responses against such rare essential protein regions, as suggested in a study on influenza (Han et al., 2019), where it was found that the selection pressure exerted by the immune system was either weak or absent.

Evolutionary selection of pathogens by a host's immune system, however, is more likely to occur for protein patterns that are general, over patterns that are rare. While essential catalytic sites in a pathogenic proteome might be relatively rare, TMHs are common and thus might be a more feasible target for evolution to respond to. Indeed, we have found the signature of evolution when both factors, that is, TMHs and catalytic sites are likely to co-occur, which is in TMPs that span the membrane at least twice. In contrast to single-spanners, where we found no significant evolutionary conservation, the TMHs of multi-spanners are more evolutionary conserved than soluble protein regions. Likely, the TMHs in many multi-spanners

need to interact which each other for correct protein structure and function and they might hence be more structurally constrained compared to the TMHs of single-spanners. Thus, we speculate that the human immune system is more attentive towards TMHs in multi-spanners, as these are evolutionarily more conserved.

There have been more efforts to assess the conservation of TMHs, using different methodologies. One such example is a study by Stevens and Arkin (Stevens and Arkin, 2001), in which aligned protein sequence data was used. Also this study found that TMHs are evolutionarily more conserved, as the mean amino acid substitution rate in TMHs is about ten percent lower, which is a similar value as we found. Another example is a study by Oberai, et al. (Oberai et al., 2009) that estimated the conservation scores for TMHs and soluble regions based on alignments of evolutionary related proteins, and also found that TMHs are more conserved, with a conservation score that was 17% higher in TMHs. Note that the last study also found that mutations in human TMHs are likelier to cause a disease, in line with our conclusion that TMHs are more conserved.

Together, from this study, two important conclusions can be drawn. First, the MHC over-presentation of TMHs is likely a general feature and predicted to occur for most alleles of both MHC-I and -II and for humans as well as bacterial and viral pathogens. Second, TMHs are genuinely more evolutionary conserved than soluble protein motifs, at least in the human proteome.

CONFLICT OF INTEREST STATEMENT

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

AUTHOR CONTRIBUTIONS

RJCB and FB conceived the idea for this research. MVB helped with the proteome analysis of *M. tuberculosis*. RJCB wrote the code. RJCB, MB, GvdB and FB wrote the article.

FUNDING

ACKNOWLEDGMENTS

SUPPLEMENTAL DATA

DATA AVAILABILITY STATEMENT

343 The data presented in the study are deposited in the Zenodo repository, accession number
344 10.5281/zenodo.5809139. Additionally, all code, intermediate and final results are archived at `https:`
345 `//github.com/richelbilderbeek/bbbq_article`.

REFERENCES

346 Ahram, M., Litou, Z. I., Fang, R., and Al-Tawallbeh, G. (2006). Estimation of membrane proteins in the
347   human proteome. *In silico biology* 6, 379–386
348 Arai, M., Mitsuke, H., Ikeda, M., Xia, J.-X., Kikuchi, T., Satake, M., et al. (2004). ConPred II: a consensus
349   prediction method for obtaining transmembrane topology models with high reliability. *Nucleic acids*
350   *research* 32, W390–W393
351 Bergseng, E., Dørum, S., Arntzen, M. Ø., Nielsen, M., Nygård, S., Buus, S., et al. (2015). Different
352   binding motifs of the celiac disease-associated hla molecules DQ2.5, DQ2.2, and DQ7.5 revealed by
353   relative quantitative proteomics of endogenous peptide repertoires. *Immunogenetics* 67, 73–84
354 Bianchi, F., Textor, J., and van den Bogaart, G. (2017). Transmembrane helices are an overlooked source
355   of Major Histocompatibility Complex Class I epitopes. *Frontiers in immunology* 8, 1118
356 Blees, A., Januliene, D., Hofmann, T., Koller, N., Schmidt, C., Trowitzsch, S., et al. (2017). Structure of
357   the human mhc-i peptide-loading complex. *Nature* 551, 525–528
358 Bougnères, L., Helft, J., Tiwari, S., Vargas, P., Chang, B. H.-J., Chan, L., et al. (2009). A role for lipid
359   bodies in the cross-presentation of phagocytosed antigens by mhc class i in dendritic cells. *Immunity* 31,
360   232–244
361 Brown, G. R., Hem, V., Katz, K. S., Ovetsky, M., Wallin, C., Ermolaeva, O., et al. (2015). Gene: a
362   gene-centered information resource at NCBI. *Nucleic acids research* 43, D36–D42
363 Dingjan, I., Verboogen, D. R., Paardekooper, L. M., Revelo, N. H., Sittig, S. P., Visser, L. J., et al. (2016).
364   Lipid peroxidation causes endosomal antigen release for cross-presentation. *Scientific reports* 6, 1–12
365 Fujimoto, T. and Ohsaki, Y. (2006). The proteasomal and autophagic pathways converge on lipid droplets.
366   *Autophagy* 2, 299–301
367 Gilleron, M., Lepore, M., Layre, E., Cala-De Paepe, D., Mebarek, N., Shayman, J. A., et al. (2016).
368   Lysosomal lipases plrp2 and lpla2 process mycobacterial multi-acylated lipids and generate t cell
369   stimulatory antigens. *Cell chemical biology* 23, 1147–1156
370 Greenbaum, J., Sidney, J., Chung, J., Brander, C., Peters, B., and Sette, A. (2011). Functional classification
371   of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising
372   degree of repertoire sharing across supertypes. *Immunogenetics* 63, 325–335
373 Gruenberg, J. (2020). Life in the lumen: the multivesicular endosome. *Traffic* 21, 76–93
374 Han, A. X., Maurer-Stroh, S., and Russell, C. A. (2019). Individual immune selection pressure has limited
375   impact on seasonal influenza virus evolution. *Nature ecology & evolution* 3, 302–311
376 Hessa, T., Meindl-Beinker, N. M., Bernsel, A., Kim, H., Sato, Y., Lerch-Bader, M., et al. (2007). Molecular
377   code for transmembrane-helix recognition by the sec61 translocon. *Nature* 450, 1026–1030
378 Istrail, S., Florea, L., Halldórsson, B. V., Kohlbacher, O., Schwartz, R. S., Yap, V. B., et al. (2004).
379   Comparative immunopeptidomics of humans and their pathogens. *Proceedings of the National Academy*
380   *of Sciences* 101, 13268–13272
381 Jones, D., Taylor, W., and Thornton, J. (1994). A model recognition approach to the prediction of all-helical
382   membrane protein structure and topology. *Biochemistry* 33, 3038–3049

383 Jones, D. T. (2007). Improving the accuracy of transmembrane protein topology prediction using
384   evolutionary information. *Bioinformatics* 23, 538–544

385 Käll, L., Krogh, A., and Sonnhammer, E. L. (2004). A combined transmembrane topology and signal
386   peptide prediction method. *Journal of molecular biology* 338, 1027–1036

387 Klammer, M., Messina, D. N., Schmitt, T., and Sonnhammer, E. L. (2009). MetaTM-a consensus method
388   for transmembrane protein topology prediction. *BMC bioinformatics* 10, 314

389 Kleijmeer, M., Ramm, G., Schuurhuis, D., Griffith, J., Rescigno, M., Ricciardi-Castagnoli, P., et al. (2001).
390   Reorganization of multivesicular bodies regulates mhc class ii antigen presentation by dendritic cells.
391   *The Journal of cell biology* 155, 53–64

392 Krogh, A., Larsson, B., Von Heijne, G., and Sonnhammer, E. L. (2001). Predicting transmembrane protein
393   topology with a hidden Markov model: application to complete genomes. *Journal of molecular biology*
394   305, 567–580

395 Larsen, M. V., Lelic, A., Parsons, R., Nielsen, M., Hoof, I., Lamberth, K., et al. (2010). Identification of
396   CD8+ T cell epitopes in the West Nile virus polyprotein by reverse-immunology using NetCTL. *PloS*
397   *one* 5, 1–11

398 Lautscham, G., Mayrhofer, S., Taylor, G., Haigh, T., Leese, A., Rickinson, A., et al. (2001). Processing of a
399   multiple membrane spanning epstein-barr virus protein for cd8+ t cell recognition reveals a proteasome-
400   dependent, transporter associated with antigen processing–independent pathway. *The Journal of*
401   *experimental medicine* 194, 1053–1068

402 Lund, O., Nielsen, M., Kesmir, C., Petersen, A. G., Lundegaard, C., Worning, P., et al. (2004). Definition
403   of supertypes for HLA molecules using clustering of specificity matrices. *Immunogenetics* 55, 797–810

404 Marsh, S. G., Albert, E., Bodmer, W., Bontrop, R., Dupont, B., Erlich, H., et al. (2010). Nomenclature for
405   factors of the HLA system, 2010. *Tissue antigens* 75, 291

406 Meusser, B., Hirsch, C., Jarosch, E., and Sommer, T. (2005). Erad: the long road to destruction. *Nature*
407   *cell biology* 7, 766–772

408 Oberai, A., Joh, N. H., Pettit, F. K., and Bowie, J. U. (2009). Structural imperatives impose diverse
409   evolutionary constraints on helical membrane proteins. *Proceedings of the National Academy of Sciences*
410   106, 17747–17750

411 Oliveira, C. C. and van Hall, T. (2015). Alternative antigen processing for mhc class i: multiple roads lead
412   to rome. *Frontiers in immunology* 6, 298

413 Peters, P. J., Neefjes, J. J., Oorschot, V., Ploegh, H. L., and Geuze, H. J. (1991). Segregation of mhc class ii
414   molecules from mhc class i molecules in the golgi complex for transport to lysosomal compartments.
415   *Nature* 349, 669–676

416 Preston, G. M. and Brodsky, J. L. (2017). The evolving role of ubiquitin modification in endoplasmic
417   reticulum-associated degradation. *Biochemical Journal* 474, 445–469

418 Rock, K. L., Reits, E., and Neefjes, J. (2016). Present yourself! by mhc class i and mhc class ii molecules.
419   *Trends in immunology* 37, 724–737

420 Sander, P., Becker, K., and Dal Molin, M. (2016). Lipase processing of complex lipid antigens. *Cell*
421   *chemical biology* 23, 1044–1046

422 Sayers, E. W., Barrett, T., Benson, D. A., Bolton, E., Bryant, S. H., Canese, K., et al. (2010). Database
423   resources of the national center for biotechnology information. *Nucleic acids research* 39, D38–D51

424 Schellens, I. M., Kesmir, C., Miedema, F., van Baarle, D., and Borghans, J. A. (2008). An unanticipated
425   lack of consensus cytotoxic T lymphocyte epitopes in HIV-1 databases: the contribution of prediction
426   programs. *Aids* 22, 33–37

427 Sette, A. and Sidney, J. (1999). Nine major hla class i supertypes account for the vast preponderance of
428   hla-a and -b polymorphism. *Immunogenetics* 50, 201–212

429 Shao, X. M., Bhattacharya, R., Huang, J., Sivakumar, I. A., Tokheim, C., Zheng, L., et al. (2020).
430   High-throughput prediction of MHC class I and II neoantigens with MHCnuggets. *Cancer Immunology*
431   *Research* 8, 396–408

432 Sherry, S. T., Ward, M.-H., Kholodov, M., Baker, J., Phan, L., Smigielski, E. M., et al. (2001). dbSNP: the
433   ncbi database of genetic variation. *Nucleic acids research* 29, 308–311

434 Sommer, S. (2005). The importance of immune gene variability (MHC) in evolutionary ecology and
435   conservation. *Frontiers in zoology* 2, 1–18

436 Stevens, T. J. and Arkin, I. T. (2001). Substitution rates in α-helical transmembrane proteins. *Protein*
437   *Science* 10, 2507–2517

438 Tang, S. T., van Meijgaarden, K. E., Caccamo, N., Guggino, G., Klein, M. R., van Weeren, P., et al.
439   (2011). Genome-based in silico identification of new Mycobacterium tuberculosis antigens activating
440   polyfunctional CD8+ T cells in human tuberculosis. *The Journal of Immunology* 186, 1068–1080

441 Velazquez-Salinas, L., Zarate, S., Eberl, S., Gladue, D. P., Novella, I., and Borca, M. V. (2020). Positive
442   selection of orf1ab, orf3a, and orf8 genes drives the early evolutionary trends of sars-cov-2 during the
443   2020 covid-19 pandemic. *Frontiers in Microbiology* 11, 2592

444 Vita, R., Mahajan, S., Overton, J. A., Dhanda, S. K., Martini, S., Cantrell, J. R., et al. (2019). The immune
445   epitope database (iedb): 2018 update. *Nucleic acids research* 47, D339–D343

446 Wang, Q., Ni, C., Li, Z., Li, X., Han, R., Zhao, F., et al. (2019). PureseqTM: efficient and accurate
447   prediction of transmembrane topology from amino acid sequence only. *bioRxiv* , 627307

448 Zwart, W., Griekspoor, A., Kuijl, C., Marsman, M., van Rheenen, J., Janssen, H., et al. (2005). Spatial
449   separation of hla-dm/hla-dr interactions within miic and phagosome-induced immune escape. *Immunity*
450   22, 221–233

FIGURE CAPTIONS

Figure 1. Over-presentation of TMH-derived epitopes on most MHC-I and -II alleles (A) The percentage of epitopes for MHC-I and -II alleles that are predicted to overlap with TMHs for the proteomes of SARS-CoV-2 (top row), human (middle row) and *M. tuberculosis* (MtB; bottom row). The pair of horizontal red lines in each plot indicate the lower and upper bound of the 99% confidence interval. See supplementary Tables ST5 and ST7 for the exact TMH and epitope counts. **(B-C)** Correlation between the percentages of predicted TMH-derived epitopes and the hydrophobicity score of all predicted epitopes for human MHC-I **(B)** and MHC-II alleles **(C)**. Diagonal red line: linear regression analysis. Labels are shorthand for the HLA alleles, see the supplementary Table ST8 for the names.

Figure 2. Analysis of epitope database shows that TMH derived epitopes are over-presented. The percentage of epitopes for MHC-I and -II alleles that overlap with TMHs that are presented. The pair of horizontal red lines in each plot indicate the lower and upper bound of the 99% confidence interval. Note that only one line is visible as this interval is relatively narrow. Alleles are listed in Table ST8. **(A)** Observed and predicted percentage of TMH-derived epitopes for MHC-I alleles. **(B)** MHC ligands from IEDB corresponding to TMH-derived epitopes. The numbers above the bars denotes the number of TMH derived epitopes obtained.

Figure 3. Evolutionary conservation of human TMHs. (A) Percentage of SNPs found in TMHs. Each point shows for one protein the predicted percentage of amino acids that are part of a TMH (x-axis) and the observed occurrence of SNPs being located within a TMH (y-axis). The dashed diagonal line shows the line of equality (i.e., equal conservation of TMHs and soluble protein regions). The diagonal red line indicates a linear fit, the gray area its 95% confidence interval. **(B)** Distribution of the percentages of TMH in the TMPs used in this study. **(C)** The number of SNPs in TMHs as expected by chance (left bar) and found in the dbSNP database (right bar). Percentages show the relative conservation of SNPs in TMHs found relative to stochastic chance.

Figure 4. Membrane proteins with multiple TMHs are evolutionary more conserved than proteins with only a single TMH. (A) Percentage of SNPs found in TMPs predicted to have only a single (left) or multiple (right) TMHs. Each point shows for one protein the predicted percentage of amino acids that are part of a TMH (x-axis) and the observed occurrence of SNPs being located within a TMH (y-axis). The dashed diagonal lines show the line of equality (i.e., equal conservation of TMHs and soluble protein regions). The diagonal red lines indicate a linear fit, the gray areas their 95% confidence intervals. **(B)** The number of SNPs in TMHs as expected by chance and observed in the dbSNP database, for TMPs with one TMH (single-spanners) and multiple TMHs (multi-spanners). Percentages show the relative conservation of SNPs in TMHs found relative to the stochastic chances. **(C)** Distribution of the proportion of amino acids residing in the plasma membrane.